Equities analysts expect Equillium (NYSE:EQ) to announce ($0.36) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Equillium’s earnings, with the highest EPS estimate coming in at ($0.27) and the lowest estimate coming in at ($0.46). Equillium posted earnings of ($0.30) per share during the same quarter last year, which indicates a negative year over year growth rate of 20%. The business is expected to announce its next earnings report on Thursday, November 21st.
According to Zacks, analysts expect that Equillium will report full-year earnings of ($1.41) per share for the current year, with EPS estimates ranging from ($1.70) to ($1.09). For the next year, analysts anticipate that the business will report earnings of ($1.83) per share, with EPS estimates ranging from ($2.23) to ($1.34). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Equillium.
Equillium (NYSE:EQ) last announced its earnings results on Monday, August 12th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04.
Institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. boosted its holdings in Equillium by 11.0% in the second quarter. Victory Capital Management Inc. now owns 1,468,727 shares of the company’s stock valued at $8,313,000 after acquiring an additional 145,346 shares during the last quarter. Paloma Partners Management Co acquired a new position in Equillium in the second quarter valued at $117,000. Edge Wealth Management LLC acquired a new position in Equillium in the second quarter valued at $40,000. Finally, Morgan Stanley boosted its holdings in Equillium by 206.0% in the second quarter. Morgan Stanley now owns 6,389 shares of the company’s stock valued at $37,000 after acquiring an additional 4,301 shares during the last quarter.
NYSE:EQ traded up $0.13 during trading hours on Tuesday, reaching $3.33. 8,213 shares of the company traded hands, compared to its average volume of 31,126. The firm’s 50-day moving average is $3.65 and its 200-day moving average is $4.83. Equillium has a 1-year low of $2.56 and a 1-year high of $19.69.
Equillium Company Profile
Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.
Recommended Story: How does a margin account work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.